Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer
This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC.
DOI: 10.3779/j.issn.1009-3419.2022.102.01 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Research Status of Tumor-associated Fibroblasts Regulating Immune Cells
Cancer-associated fibroblasts (CAFs) and tumor-infiltrating immune cells are the most essential components of the tumor microenvironment (TME). They communicate with each other in tumor microenvironment and play a critical role in tumorigenesis and development. CAFs are very heterogeneous and different subtypes of CAFs display different functions. At the same time, it can contribute to the regulation of the function of tumor-infiltrating immune cells and eventually result in the carcinogenesis, tumor progression, invasion, metastasis and other biological behaviors of tumors by producting various growth factors and cytokine...
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Immunotherapy for Non-small Cell Lung Cancer
with Drive Gene Mutation
Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has “driver gene mutations” and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, t he efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients w...
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer
This article reviews the high risk factors of brain metastasis in NSCLC.
DOI: 10.3779/j.issn.1009-3419.2022.101.08 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer
with Epidermal Growth Factor Receptor Gene Mutation
Lung cancer is the sixth leading cause of death worldwide and one of the leading cause of death from malignant tumors. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) gene mutation is a common mutation in NSCLC. For advanced NSCLC patients with EGFR mutations, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib, Afatinib, Oxitinib and other targeted therapies have become the first-line treatment recommended by many guidelines, but many patients develop acquired drug resistance after about 1 year of medication. Patients with drug resistance will h...
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer
With the rapid development and wide application of next generation sequencing (NGS) technology, a series of researches have revealed that concurrent genetic alterations play an important role in the response and resistance of epidermal growth factor receptor (EGFR)-mutant NSCLC to EGFR-tyrosine kinase inhibitor (TKI). Besides, TP53 mutation is the most common co-mutation gene in EGFR-mutant NSCLC, which has been proved to confer a worse prognosis in EGFR-mutated patients treated with first, second and third generation of EGFR-TKIs. Currently, it is still being explored how to select the best treatment strategies for patien...
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Analysis on the Incidence and Economic Burden of Patients with Lung Cancer
Conclusion Lung cancer is still one of the main cancers endangering the health of Chinese residents. The incidence of lung cancer is increasing year by year, and the distribution of gender and age has certain characteristics. In order to reduce the number of cases and the economic burden, effective prevention and control measures should be formulated and medical reform should be strengthened.
DOI: 10.3779/j.issn.1009-3419.2022.101.09 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients
Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis:
A Single-center Retrospective Study
This study was designed to explore the clinical characteristics and prognostic factors of these patients in order to provide management recommendations for them. Methods A retrospective analysis of the clinical characteristics, treatment, outcomes and progression-free survival (PFS) of first-line treatment in patients with EGFR mutated lung adenocarcinoma combined with pleural effusion at initial diagnosis admitted to Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital from January 2012 to June 2021 was performed. Pearson ' s chi-square test or Fisher ' s exact test were performed for co...
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Relationship between EGFR, ALK Gene Mutation and Imaging
and Pathological Features in Invasive Lung Adenocarcinoma
Conclusion The EGFR and ALK genes mutated adenocarcinomas have specific imaging and clinicopathological features, and the mutations in exon 19 or exon 21 subtype have different imaging features, which is of great significance in guiding the clinical diagnosis and treatment of pulmonary nodules.
DOI: 10.3779/j.issn.1009-3419.2022.101.10 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - March 20, 2022 Category: Cancer & Oncology Source Type: research
Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer
Conclusion In patients with locally advanced central NSCLC after neoadjuvant chemoimmunotherapy can achieve the tumor reduction, tumor stage decline and increase the R0 resection rate, bronchial sleeve resection is safe and feasible. Under the premise of following the two principles of surgical safety and realizing the tumor R0 resection, robot-assisted bronchial sleeve resection can be preferred.
DOI: 10.3779/j.issn.1009-3419.2021.101.46 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - February 28, 2022 Category: Cancer & Oncology Source Type: research
Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer
Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downstage rates and pathological remission in the neoadjuvant setting. Predictive biomarkers are of great significance to identify the beneficiaries of neoadjuvant ICIs. At present, the biomarkers are still inconclusive. We summarized the clinical trials of neoadjuvant immune checkpoint inhibitors that have been disclosed so far, and...
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress in 3D-reconstruction Based Imaging Analysis
in Partial Solid Pulmonary Nodule
This article focuses on the traditional imaging analysis of partial solid nodules and the imaging analysis based on 3D reconstruction, and systematically expounds the advantages and disadvantages of both.
DOI: 10.3779/j.issn.1009-3419.2022.101.03 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
Application and Progress of Electromagnetic Navigation Bronchoscopy in Department of Thoracic Surgery
Lung cancer ranks the first cancer-related morbidity and mortality in China. With the development and penetration of imaging technology, increasing small pulmonary peripheral Nodules (SPPNs) have been detected. However, precise location and diagnosis of SPPNs is still a tough problem for clinical diagnosis and treatment in department of thoracic surgery. With the development of electromagnetic navigation bronchoscopy (ENB), it provides a novel minimally invasive method for the diagnosis and treatment of SPPNs. In this review, we summarized the application and progress of ENB in preoperative positioning, diagnosis, and loca...
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
Lung Cancer Stem-like Cells and Drug Resistance
Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung cancer tissues and cell lines, possessing the abilities of self-renewal, multipotent differentiation and unlimited proliferation. These lung cancer stem-like cells (LCSCs) can generate tumors with high effeciency in vivo, survive cytotoxic therapies, and eventually lead to therapy resistance and recurrence. In this review, we would ...
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
Dual Immunotherapy in Advanced Non-small Cell Lung Cancer:
the Progress and Clinical Application
This article reviews the mechanism of action, research progress, predictive biomarkers and future exploration directions of dual immunotherapy.
DOI: 10.3779/j.issn.1009-3419.2021.102.48 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
